๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Inflammatory Myositis

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease NCT06379646NA1 site๐Ÿ“ Shanghai China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 Rare AutoImmune SElf-management Programme Development NCT06642870n/a1 site๐Ÿ“ Bristol University of the West of England ยท Tests: Non-interventional study Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD19- BCMA CAR-T cells CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: UCAR T-cell Adult and Juvenile Myositis NCT00017914n/a4 sites๐Ÿ“ Atlanta๐Ÿ“ Bethesda๐Ÿ“ Research Triangle Park National Institute of Environmental Health Sciences (NIEHS) Safety and Efficacy of Universal CD19-targeting CAR-ฮณฮดT Cells in Refractory Autoimmune Diseases NCT06828042Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University Third Hospital ยท Tests: anti-CD19 CAR T cell therapy CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: QT-019C An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases NCT07174843EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Cell Therapy Group Co.,Ltd ยท Tests: CD19/CD22/BCMA CAR-T cells(BZE2204) A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) NCT06733935Phase 1, Phase 218 sites๐Ÿ“ Orange๐Ÿ“ Gainesville๐Ÿ“ Miami Nkarta, Inc. ยท Tests: NKX019, Fludarabine, Cyclophosphamide BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: BCMA-CD19 CAR-T therapy Inspiratory Muscle Training in Patients With Inflammatory Myopathy NCT07274267NA1 site๐Ÿ“ Warsaw Jรณzef Piล‚sudski University of Physical Education ยท Tests: Inspiratory Muscle Training (IMT) MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) NCT07374107n/a1 site๐Ÿ“ New Orleans Myositis International Health & Research Collaborative Alliโ€ฆ ยท Tests: No intervention - qualitative and mixed methods investigations Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) NCT07160205Phase 2, Phase 32 sites๐Ÿ“ Gainesville๐Ÿ“ Miami Restem, LLC. ยท Tests: ULSC (1.5 x 10^8 cells/dose), Placebo (no cells) Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases NCT06599411n/a1 site๐Ÿ“ Paris Assistance Publique - Hรดpitaux de Paris ยท Tests: Sampling, Sampling A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647Phase 11 site๐Ÿ“ Beijing China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 cell Optimizing Treatment on Idiopathic Inflammatory Myopathies NCT03092180n/a1 site๐Ÿ“ Sรฃo Paulo University of Sao Paulo ยท Tests: Intravenous Infusion A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies NCT06698796Phase 326 sites๐Ÿ“ Glendale๐Ÿ“ Frisco๐Ÿ“ Houston Pfizer ยท Tests: Dazukibart Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site๐Ÿ“ Jerusalem Polina Stepensky ยท Tests: HBI0101 CART GC012F Injection in Refractory Idiopathic Inflammatory Myopathy NCT07086404EARLY Phase 11 site๐Ÿ“ Wuhan Daishi Tian ยท Tests: GC012F Injection infusion Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients NCT07249060n/a1 site๐Ÿ“ Pamplona Hospital Universitario Araba ยท Tests: Immune Checkpoint Inhibitors A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) NCT06455449Phase 3237 sites๐Ÿ“ Phoenix๐Ÿ“ Irvine๐Ÿ“ Aurora AstraZeneca ยท Tests: Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label) BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy NCT07715136Phase 11 site๐Ÿ“ Chengdu iCell Gene Therapeutics ยท Tests: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T AlloNKยฎ, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. NCT06991114Phase 252 sites๐Ÿ“ Tuscaloosa๐Ÿ“ Phoenix๐Ÿ“ Tucson Artiva Biotherapeutics, Inc. ยท Tests: Allogeneic NK Cells A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease NCT06308978Phase 121 sites๐Ÿ“ Beverly Hills๐Ÿ“ Fullerton๐Ÿ“ Irvine Fate Therapeutics ยท Tests: FT819, Fludarabine, Cyclophosphamide, Bendamustine A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases NCT07115745Phase 128 sites๐Ÿ“ Boston๐Ÿ“ Durham๐Ÿ“ Camperdown Juno Therapeutics, Inc., a Bristol-Myers Squibb Company ยท Tests: BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] NCT05895786Phase 3138 sites๐Ÿ“ Glendale๐Ÿ“ Phoenix๐Ÿ“ Phoenix Pfizer ยท Tests: PF-06823859, Placebo A Study of AZD0120 in Autoimmune Diseases NCT07295847Phase 122 sites๐Ÿ“ Tucson๐Ÿ“ Stanford๐Ÿ“ Chicago AstraZeneca ยท Tests: AZD0120 Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases NCT07236801Phase 12 sites๐Ÿ“ Xuzhou๐Ÿ“ Xuzhou China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 cell Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty NCT07138898Phase 21 site๐Ÿ“ New York NYU Langone Health ยท Tests: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease NCT06925542Phase 117 sites๐Ÿ“ La Jolla๐Ÿ“ Redwood City๐Ÿ“ Chicago CRISPR Therapeutics ยท Tests: CTX112
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy